Cleveland Diagnostics Receives College of American Pathologists (CAP) Accreditation for Its Clinical Laboratory
— Clinical Laboratory Meets the Highest Standards in Laboratory Practice — CLEVELAND–(BUSINESS WIRE)–Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its CLIA certified reference lab. The CAP Accreditation is awarded […]
Cleveland Diagnostics Presents New Data Supporting the Clinical Validation and Clinical Utility of IsoPSA at the 2021 Annual Meeting of American Urological Association
IsoPSA clinically validated in a study of over 1000 patients and demonstrates significant clinical utility in a study of 900 patients in a real-world setting CLEVELAND–(BUSINESS WIRE)–Cleveland Diagnostics, Inc., a commercial stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that Eric Klein, MD, Chairman of the Glickman Urological […]
Cleveland Diagnostics Announces Publication of Real-World Study Demonstrating the Clinical Utility of IsoPSA® for Prostate Cancer Risk Assessment
The use of IsoPSA significantly changed provider behavior, leading to a 55 percent reduction in prostate biopsy recommendations CLEVELAND–(BUSINESS WIRE)–Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today the publication of a large real-world clinical utility study in Urology Practice, a peer-reviewed journal of the American Urological […]